A safety evaluation of cangrelor in patients undergoing PCI

Expert Opinion on Drug Safety

Volumn 15, Issue 2, 2016, Pages 275-285

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Park, Yongwhi ^a,b   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Gyeongsang National University   (South Korea)

Author keywords

Acute coronary syndrome; antiplatelet therapy; cangrelor; P2Y12 receptor antagonist; percutaneous coronary intervention

Indexed keywords

CANGRELOR; ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOT LYSIS; CONCENTRATION AT STEADY-STATE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DYSPNEA; HUMAN; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; DRUG INTERACTION; HALF LIFE TIME; PROCEDURES;

ADENOSINE MONOPHOSPHATE; ASPIRIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HALF-LIFE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS;

EID: 84958161077     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1133585     Document Type: Review

References (67)

1. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007; 357: 2482-2494
2. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010; 74: 597-607
3. Angiolillo DJ The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs. 2012; 72: 2087-2116
4. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015; 12: 30-47
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49 (14): 1505-1516
6. Michelson AD, Frelinger AL 3rd, Braunwald E., et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009; 30: 1753-1763
7. Storey RF, Angiolillo DJ, Patil SB., et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient outcomes) PLATELET substudy. J Am Coll Cardiol. 2010; 56: 1456-1462
8. Franchi F, Rollini F, Cho JR., et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv. 2015; 8: 1457-1467
9. Alexopoulos D, Xanthopoulou I, Gkizas V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2012; 5: 797-804
10. Parodi G, Valenti R, Bellandi B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol. 2013; 61: 1601-1606
11. Franchi F, Rollini F, Angiolillo DJ. Perspectives on the management of antiplatelet therapy in patients with coronary artery disease requiring cardiac and noncardiac surgery. Curr Opin Cardiol. 2014; 29: 553-563
12. Capodanno D, Angiolillo DJ. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines. Circ Cardiovasc Interv. 2015; 8: e002301
13. Franchi F, Rollini F, Muñiz-Lozano A., et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther. 2013; 11: 1279-1291
14. Hechler B, Vigne P, Léon C., et al. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol Pharmacol. 1998; 53: 727-733
15. Ingall AH, Dixon J, Bailey A., et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J Med Chem. 1999; 42: 213-220
16. Van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost. 2005; 31: 195-204
17. Akers WS, Oh JJ, Oestreich JH., et al. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist. J Clin Pharmacol. 2010; 50: 27-35
18. Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost. 2001; 85: 401-407
19. Angiolillo DJ, Firstenberg MS, Price MJ., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-274
20. Angiolillo DJ, Schneider DJ, Bhatt DL., et al. Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. J Thromb Thrombolysis. 2012; 34: 44-55
21. Nassim MA, Sanderson JB, Clarke C., et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J Am Coll Cardiol. 1999; 33 (2 Suppl A): A255
22. Javis GE, Nassim MA, Humphries RG., et al The P2Y antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood. 1999; 94 (Suppl. 1): A22
23. Aleil B, Ravanat C, Cazenave JP., et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. 2005; 3: 85-92
24. Rollini F, Franchi F, Tello-Montoliu A., et al. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-Treated patients. JACC Cardiovasc Interv. 2014; 7: 426-434
25. Ferreiro JL, Ueno M, Tello-Montoliu A., et al. Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. J Thromb Thrombolysis. 2013; 35: 155-164
26. Greenbaum AB, Ohman EM, Gibson CM., et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am Heart J. 2007; 154: 702-709
27. Greenbaum AB, Grines CL, Bittl JA., et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-And active-controlled trial. Am Heart J. 2006; 151: 689.e1-689.e10
28. Harrington RA, Stone GW, McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361: 2318-2329
29. Bhatt DL, Lincoff AM, Gibson CM., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009; 361: 2330-2341
30. White HD, Chew DP, Dauerman HL., et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J. 2012; 163: 182-90.e4
31. Bhatt DL, Stone GW, Mahaffey KW., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013; 368: 1303-1313
32. Généreux P, Stone GW, Harrington RA., et al. Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014; 63: 619-629
33. Steg PG, Bhatt DL, Hamm CW., et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level datA Lancet. 2013; 382: 1981-1992
34. Cangrelor United States full prescribing information; [. cited 2015 Oct 29 ]. Available from: www.kengreal.com/pdfs/kengreal-us-prescribing-information.pdf
35. Cangrelor EMA prescribing information; [. cited 2015 Oct 29 ]. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/003773/WC500188098.pdf
36. Mehran R, Pocock SJ, Stone GW., et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J. 2009; 30: 1457-1466
37. Chhatriwalla AK, Amin AP, Kennedy KF., et al. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309: 1022-1029
38. Eikelboom JW, Mehta SR, Anand SS., et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006; 114: 774-782
39. Mehran R, Rao SV, Bhatt DL., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123: 2736-2747
40. Kikkert WJ, Van Geloven N, Van Der Laan MH The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. J Am Coll Cardiol. 2014; 63: 1866-1875
41. Ndrepepa G, Schuster T, Hadamitzky M., et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2012; 125: 1424-1431
42. Gutierrez JA, Harrington RA, Blankenship JC., et al The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2015 [cited 2015 Sep 23 ]. doi: 10.1093/eurheartj/ehv498
43. Doyle BJ, Rihal CS, Gastineau DA., et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009; 53: 2019-2027
44. Muñiz-Lozano A, Rollini F, Franchi F., et al. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis. 2013; 7: 197-213
45. Stone GW, Mehran R, Steg PG. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes. JACC Cardiovasc Interv. 2015; 8: 225-227
46. White HD, Bhatt DL, Gibson CM., et al. Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015; 8: 424-433
47. Unverdorben M, Parodi G, Pistolesi M., et al. Dyspnea related to reversibly-binding P2Y12 inhibitors: a review of the pathophysiology, clinical presentation and diagnostics. Int J Cardiol. 2015; 202: 167-173
48. Cattaneo M, Schulz R, Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol. 2014; 63: 2503-2509
49. Cattaneo M, Faioni EM. Why does ticagrelor induce dyspnea? Thromb Haemost. 2012; 108: 1031-1036
50. Ranhosky A, Kempthorne-Rawson J The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation. 1990; 81: 1205-1209
51. Alexander KP, Chen AY, Roe MT., et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294: 3108-3116
52. Angiolillo DJ, Bhatt DL, Steg PG., et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis. 2015; 40: 317-322
53. Green CL, Whellan DJ, Lambe L., et al. Electrocardiographic safety of cangrelor, a new intravenous antiplatelet agent: a randomized, double-blind, placebo-And moxifloxacin-controlled thorough QT study. J Cardiovasc Pharmacol. 2013; 62: 466-478
54. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol. 2016; 13: 11-27
55. Steinhubl SR, Oh JJ, Oestreich JH., et al. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res. 2008; 121: 527-534
56. Dovlatova NL, Jakubowski JA, Sugidachi A., et al The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost. 2008; 6: 1153-1159
57. Schneider DJ, Agarwal Z, Seecheran N., et al. Pharmacodynamic effects during the transition between cangrelor and ticagrelor. JACC Cardiovasc Interv. 2014; 7: 435-442
58. Schneider DJ, Seecheran N, Raza SS., et al. Pharmacodynamic effects during the transition between cangrelor and prasugrel. Coron Artery Dis. 2015; 26: 42-48
59. Schneider DJ, Agarwal Z, Seecheran N., et al. Pharmacodynamic effects when clopidogrel is given before cangrelor discontinuation. J Interv Cardiol. 2015; 28: 415-419
60. Collet JP, Funck-Brentano C, Prats J., et al. Intravenous clopidogrel (MDCO-157) compared with oral clopidogrel: the randomized cross-over AMPHORE study. Am J Cardiovasc Drugs. 2015 [cited 2015 Sep 19 ]. doi: 10.1007/s40256-015-0145-0
61. Cushing DJ, Souney PF, Cooper WD., et al. Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans: effects of intravenous clopidogrel. Clin Exp Pharmacol Physiol. 2012; 39: 3-8
62. Ueno M, Rao SV, Angiolillo DJ. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010; 6: 445-453
63. Welsh RC, Rao SV, Zeymer U., et al A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012; 5: 336-346
64. Angiolillo DJ, Welsh RC, Trenk D., et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circ Cardiovasc Interv. 2012; 5: 347-356
65. Stone GW, Mehran R, Goldstein P., et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol. 2015; 65: 27-38
66. Roffi M, Patrono C, Collet JP., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J. 2015 [cited 2015 Aug 29 ]. doi: 10.1093/eurheartj/ehv320
67. Parodi G, Xanthopoulou I, Bellandi B., et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015; 65: 511-512